STAT5B and neoplasm: Jak2 is often amplified in TNBC cell lines and specific inhibition of Jak2-STAT5 signaling with the drug ruxolitinib reduced proliferation of cells in culture, as well as tumor growth in vivo [153], suggesting this is a good avenue for developing treatment regimes.